licogliflozin
Small moleculeexperimental
Clinical trial activity
12 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
12
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01407003)
Timeline
Indications
Mechanism of action
- Sodium/glucose cotransporter 2INHIBITOR
SLC5A2 inhibitor
- Sodium/glucose cotransporter 1INHIBITOR
Sodium/glucose cotransporter 1 inhibitor
Dual SGLT1/2 inhibitor.
Chemistry & pharmacology
Loading structure…
SMILES
CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2- Mol. weight
- 416.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297625 ↗
Also known as
- lik066
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04065841 | Phase 2 | Dec 10, 2019 | Novartis |
| NCT03320941 | Phase 2 | Dec 7, 2017 | Novartis |
| NCT03205150 | Phase 2 | Oct 4, 2017 | Novartis |
| NCT03152552 | Phase 2 | Jun 30, 2017 | Novartis |
| NCT03152591 | Phase 2 | Jun 29, 2017 | Novartis |
| NCT03198767 | Phase 2 | Jun 21, 2017 | Novartis |
| NCT03100058 | Phase 2 | May 6, 2017 | Novartis |
| NCT03131479 | Phase 2 | Apr 28, 2017 | Novartis |
| NCT01824264 | Phase 2 | Nov 1, 2015 | Novartis |
| NCT02470403 | Phase 2 | Jun 5, 2015 | Novartis |
| NCT01915849 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2013 | Novartis |
| NCT01407003 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2011 | Novartis |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 12 | 12 | 1 | 2011 |
1 organizations
Page 1 / 1